Mereo Biopharma Group Stock Z Score
| MREO Stock | USD 4.53 0.09 1.95% |
Mereo | Z Score |
Mereo BioPharma Group Company Z Score Analysis
Mereo BioPharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Mereo Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Mereo BioPharma is extremely important. It helps to project a fair market value of Mereo Stock properly, considering its historical fundamentals such as Z Score. Since Mereo BioPharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mereo BioPharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mereo BioPharma's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Mereo BioPharma Group has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Mereo BioPharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Mereo BioPharma from analyzing Mereo BioPharma's financial statements. These drivers represent accounts that assess Mereo BioPharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Mereo BioPharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 221.0M | 884.9M | 624.0M | 374.0M | 1.5B | 1.6B | |
| Enterprise Value | 237.0M | 879.4M | 546.4M | 330.4M | 1.5B | 1.5B |
Mereo BioPharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mereo BioPharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mereo BioPharma's managers, analysts, and investors.Environmental | Governance | Social |
Mereo BioPharma Institutional Holders
Institutional Holdings refers to the ownership stake in Mereo BioPharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mereo BioPharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mereo BioPharma's value.| Shares | Goldman Sachs Group Inc | 2024-06-30 | 2.5 M | Integral Health Asset Management, Llc | 2024-06-30 | 1.8 M | Renaissance Technologies Corp | 2024-06-30 | 1.8 M | Perceptive Advisors Llc | 2024-06-30 | 1.3 M | Soleus Capital Management, L.p. | 2024-06-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.1 M | Neos Investment Management, Llc | 2024-06-30 | 959.5 K | Blue Owl Capital Holdings Lp | 2024-06-30 | 897.8 K | Susquehanna International Group, Llp | 2024-06-30 | 840.3 K | Rubric Capital Management Lp | 2024-06-30 | 15.3 M | Adage Capital Partners Gp Llc | 2024-06-30 | 11.8 M |
Mereo Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (37.90) % | ||||
| Current Valuation | 629.53 M | ||||
| Shares Outstanding | 153.85 M | ||||
| Shares Owned By Insiders | 1.02 % | ||||
| Shares Owned By Institutions | 65.48 % | ||||
| Number Of Shares Shorted | 4.88 M | ||||
| Price To Earning | 6.73 X | ||||
| Price To Book | 9.04 X | ||||
| Price To Sales | 710.80 X | ||||
| Revenue | 10 M | ||||
| Gross Profit | 936 K | ||||
| EBITDA | (23.95 M) | ||||
| Net Income | (29.47 M) | ||||
| Cash And Equivalents | 94.3 M | ||||
| Cash Per Share | 0.81 X | ||||
| Total Debt | 5.95 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 7.92 X | ||||
| Book Value Per Share | 0.51 X | ||||
| Cash Flow From Operations | (21.13 M) | ||||
| Short Ratio | 6.19 X | ||||
| Earnings Per Share | (0.25) X | ||||
| Target Price | 7.23 | ||||
| Number Of Employees | 33 | ||||
| Beta | 0.97 | ||||
| Market Capitalization | 710.8 M | ||||
| Total Asset | 66.5 M | ||||
| Retained Earnings | (419.63 M) | ||||
| Working Capital | 54.27 M | ||||
| Current Asset | 94 K | ||||
| Current Liabilities | 729 K | ||||
| Net Asset | 66.5 M |
About Mereo BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mereo BioPharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mereo BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mereo BioPharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Mereo Stock
| 0.6 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.47 | MNMD | Mind Medicine | PairCorr |
| 0.46 | INAB | In8bio Inc | PairCorr |
| 0.46 | LPCN | Lipocine | PairCorr |
| 0.37 | INKT | Mink Therapeutics | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Mereo BioPharma Piotroski F Score and Mereo BioPharma Valuation analysis. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.